Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma

On November 3, 2023 Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets reported multispecific molecules targeting GPRC5D, BCMA, and CD3 this week during the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) conference in San Diego (Press release, Integral Molecular, NOV 3, 2023, View Source [SID1234636887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients. A trispecific antibody that simultaneously engages these molecules while activating T cells is expected to provide comparable and additional benefits as a monotherapy.

Integral Molecular’s oncology drug discovery program has yielded a panel of high affinity bispecific and trispecific molecules targeting GPRC5D, a GPCR target with complex structural biology. The molecules show picomolar cell-killing activity and are highly selective for their targets.

"For decades we have navigated the complexities of molecules like GPRC5D, successfully discovering antibodies against even the most challenging targets," said Joseph Rucker, PhD, VP of R&D at Integral Molecular. "In just a few short months we were able to simultaneously target GPRC5D and BCMA, and we expect to rapidly advance this molecule into preclinical studies."

The company leveraged its MPS antibody discovery platform to discover and engineer antibodies for this program. MPS is unique from other platforms in the use of RNA, DNA, and virus-like particles (VLPs, or Lipoparticles) to present properly folded membrane proteins, and the use of divergent species (chickens) to generate diverse antibody responses.

Dr. Rucker will present the company’s bi- and trispecific GPRC5D antibodies in a poster during the SITC (Free SITC Whitepaper) 2023 conference. GPRC5D and other antibody assets from Integral Molecular are available for licensing.